Wall Street brokerages expect that Teligent Inc (NASDAQ:TLGT) will post $19.80 million in sales for the current quarter, according to Zacks. Two analysts have made estimates for Teligent’s earnings. The lowest sales estimate is $19.10 million and the highest is $20.50 million. Teligent reported sales of $13.66 million during the same quarter last year, which indicates a positive year over year growth rate of 44.9%. The firm is scheduled to issue its next quarterly earnings results on Monday, November 5th.
According to Zacks, analysts expect that Teligent will report full year sales of $72.27 million for the current financial year, with estimates ranging from $72.03 million to $72.50 million. For the next fiscal year, analysts expect that the firm will report sales of $98.70 million, with estimates ranging from $90.90 million to $106.50 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research firms that cover Teligent.
Teligent (NASDAQ:TLGT) last issued its earnings results on Wednesday, August 8th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.02) by ($0.18). Teligent had a negative return on equity of 50.85% and a negative net margin of 62.19%. The business had revenue of $16.75 million during the quarter, compared to the consensus estimate of $16.06 million.
NASDAQ TLGT traded up $0.05 during trading hours on Thursday, reaching $3.26. The company’s stock had a trading volume of 134,900 shares, compared to its average volume of 537,131. The company has a quick ratio of 1.79, a current ratio of 2.77 and a debt-to-equity ratio of 3.31. Teligent has a 52 week low of $2.43 and a 52 week high of $5.58. The stock has a market capitalization of $172.39 million, a P/E ratio of -17.16 and a beta of 1.13.
In other Teligent news, CEO Jason Grenfell-Gardner sold 52,800 shares of the firm’s stock in a transaction dated Tuesday, September 4th. The shares were sold at an average price of $4.00, for a total value of $211,200.00. Following the transaction, the chief executive officer now owns 94,949 shares of the company’s stock, valued at $379,796. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 22.80% of the company’s stock.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. raised its holdings in shares of Teligent by 1.2% during the second quarter. BlackRock Inc. now owns 3,447,407 shares of the company’s stock valued at $11,928,000 after buying an additional 40,310 shares during the last quarter. Prosight Management LP raised its holdings in shares of Teligent by 34.5% during the second quarter. Prosight Management LP now owns 3,325,000 shares of the company’s stock valued at $11,505,000 after buying an additional 852,439 shares during the last quarter. Sanders Morris Harris LLC raised its holdings in shares of Teligent by 93.6% during the second quarter. Sanders Morris Harris LLC now owns 1,489,057 shares of the company’s stock valued at $5,152,000 after buying an additional 720,075 shares during the last quarter. First Light Asset Management LLC raised its holdings in shares of Teligent by 4.6% during the second quarter. First Light Asset Management LLC now owns 1,151,032 shares of the company’s stock valued at $3,983,000 after buying an additional 50,209 shares during the last quarter. Finally, Northpointe Capital LLC bought a new stake in shares of Teligent during the third quarter valued at approximately $2,948,000. 68.27% of the stock is currently owned by institutional investors.
Teligent Company Profile
Teligent, Inc, a specialty generic pharmaceutical company, develops, manufactures, and markets generic topical, branded generic, and generic injectable pharmaceutical products in the United States and Canada. The company sells generic pharmaceutical products in topical, injectable, complex, and ophthalmic dosage forms.
Featured Story: How Important is Technical Analysis of Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Teligent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teligent and related companies with MarketBeat.com's FREE daily email newsletter.